CytoImmune Therapeutics and Biosimilar Solutions Establish Puerto Rico Production Facilities

Date Published02/04/2021
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Biosimilar Solutions
Type of work Manufacturing
Reshoring category:Reshoring
Year reshoring announced:2021
Year reshoring implemented or to be implemented:2021
Domestically, the work will be done:In-house
Capital investment ($):200
Country(ies) from which reshored:United States
City reshored to:Aguadilla
State(s) reshored to:PR
If relevant, work nearshored to:-
Product(s) reshoredrecombinant biotechnologies, COVID-19 vaccine
What domestic positive factors made reshoring more attractive?Eco-system synergies, Infrastructure, Raw Materials Cost, Skilled workforce availability/training, Other, Covid-19
Find Reshoring Articles